A U.S. study of over 500 youth aged 14–24 found high awareness but widespread hesitation about using semaglutide for weight ...

A U.S. judge on Thursday rejected a bid by compounding pharmacies to keep making copies of Novo Nordisk's popular diabetes ...

Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several ...

A daily pill could be as effective for weight loss as popular drugs like Wegovy and Ozempic, providing an alternative to the ...

These are referred to as compounded drugs, which, while containing some of the same ingredients, are not identical to the ...

Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

Novo Nordisk (NYSE: NVO) has filed for U.S. approval of an oral version of its blockbuster weight loss drug Wegovy, the company confirmed to BioPharma Dive. The Danish drugmaker disclosed the ...

A daily pill developed by the US pharmaceutical company Lilly may become a convenient alternative to injectable drugs like Ozempic and Wegovy. In phase III trials it significantly lowered blood sugar ...

"With the FDA announcing the resolution of shortages for Semaglutide (Wegovy, Ozempic) and Tirzepatide (Zepbound, Mounjaro), compounding pharmacies must halt production of these medications. This ...

Federal law allows compounding pharmacies to make copies of name brand drugs while there’s a supply shortage. But there's a ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.